Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://cesarv537ufs7.wikimeglio.com/user